Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Terray Therapeutics today announced the appointment of industry veteran Elliott Levy, MD, to the company's Scientific Advisory Board. Terray is a biotechnology company improving human health by ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Leading pharmacy benefit managers are shifting away from lucractive rebates on biologic drugs and toward lower-cost ...

Motley Fool Asset Management increased its stake in Amgen by 13% in Q4, acquiring over 2,800 new shares. This brought their ...

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

Groupama Asset Management cut its stake in Amgen by nearly 15% in Q4, selling off over 3,000 shares. At quarter’s end, their ...

President Donald Trump’s exemption of pharmaceuticals from “reciprocal” tariffs limited the declines of biopharma stocks as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.